Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 4
2018 1
2019 3
2020 11
2021 23
2022 16
2023 19
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Vadadustat: First Approval.
Markham A. Markham A. Drugs. 2020 Sep;80(13):1365-1371. doi: 10.1007/s40265-020-01383-z. Drugs. 2020. PMID: 32852744 Review.
Vadadustat (VAFSEO()) is a prolyl hydroxylase inhibitor being developed by Akebia Therapeutics, Inc. ...This article summarizes the milestones in the development of vadadustat leading to this first approval....
Vadadustat (VAFSEO()) is a prolyl hydroxylase inhibitor being developed by Akebia Therapeutics, Inc. ...This article summarizes the m …
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, Khawaja Z, Koury MJ, Maroni BJ, Matsushita K, McCullough PA, Lewis EF, Luo W, Parfrey PS, Pergola P, Sarnak MJ, Spinowitz B, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Zwiech R, Chertow GM. Eckardt KU, et al. N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956. N Engl J Med. 2021. PMID: 33913638 Clinical Trial.
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogenous erythropoietin production. ...RESULTS: A total of 3923 patients were randomly assigned in a 1:1 ratio to receive vadadustat or dar …
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, a class of compounds that stimulate endogeno …
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
Chertow GM, Pergola PE, Farag YMK, Agarwal R, Arnold S, Bako G, Block GA, Burke S, Castillo FP, Jardine AG, Khawaja Z, Koury MJ, Lewis EF, Lin T, Luo W, Maroni BJ, Matsushita K, McCullough PA, Parfrey PS, Roy-Chaudhury P, Sarnak MJ, Sharma A, Spinowitz B, Tseng C, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Eckardt KU; PRO2TECT Study Group. Chertow GM, et al. N Engl J Med. 2021 Apr 29;384(17):1589-1600. doi: 10.1056/NEJMoa2035938. N Engl J Med. 2021. PMID: 33913637 Clinical Trial.
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production. ...RESULTS: A total of 1751 patients with ESA-untreated NDD-CKD and 1725 with ESA-treate …
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF an …
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.
Sarnak MJ, Agarwal R, Boudville N, Chowdhury PCP, Eckardt KU, Gonzalez CR, Kooienga LA, Koury MJ, Ntoso KA, Luo W, Parfrey PS, Vargo DL, Winkelmayer WC, Zhang Z, Chertow GM. Sarnak MJ, et al. Nephrol Dial Transplant. 2023 Sep 29;38(10):2358-2367. doi: 10.1093/ndt/gfad074. Nephrol Dial Transplant. 2023. PMID: 37096396 Free PMC article. Clinical Trial.
Vadadustat's effects in patients receiving only peritoneal dialysis is unclear. ...RESULTS: Of the 3923 patients randomized in the two INNO2VATE trials, 309 were receiving peritoneal dialysis (vadadustat, n = 152; darbepoetin alfa, n = 157) at baseline. Time to firs …
Vadadustat's effects in patients receiving only peritoneal dialysis is unclear. ...RESULTS: Of the 3923 patients randomized in the tw …
Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis.
Huang Q, Liao Z, Liu X, Xia Y, Wang J. Huang Q, et al. Int Urol Nephrol. 2023 Feb;55(2):325-334. doi: 10.1007/s11255-022-03316-z. Epub 2022 Aug 12. Int Urol Nephrol. 2023. PMID: 35960479 Review.
Vadadustat may become an effective and safe alternative for the treatment of patients with anemia and CKD, especially in NDD-CKD patients. As the application of vadadustat is still under exploration, future research should compensate for the limitations of our study …
Vadadustat may become an effective and safe alternative for the treatment of patients with anemia and CKD, especially in NDD-CKD pati …
Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Xiong L, Zhang H, Guo Y, Song Y, Tao Y. Xiong L, et al. Front Pharmacol. 2022 Jan 18;12:795214. doi: 10.3389/fphar.2021.795214. eCollection 2021. Front Pharmacol. 2022. PMID: 35115942 Free PMC article. Review.
Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney disease (CKD), but its effect and safety remain uncertain. ...Conclusion: Vadadustat may safely improve Hb levels and promote iron utilization in CKD patients with anemia without …
Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney disease (CKD), but its effect and safety rema …
Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open-label study in Japan.
Nangaku M, Kondo K, Takabe S, Ueta K, Kaneko G, Otsuka M, Kawaguchi Y, Komatsu Y. Nangaku M, et al. Ther Apher Dial. 2021 Oct;25(5):642-653. doi: 10.1111/1744-9987.13611. Epub 2020 Dec 29. Ther Apher Dial. 2021. PMID: 33283981 Free PMC article. Clinical Trial.
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in patients with chronic kidney disease (CKD). ...The most frequent adverse events were catheter site infections (23.8%), which were not related to vadadustat tre …
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in patients with chronic kidn …
Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells.
Zielniok K, Burdzinska A, Kaleta B, Zagozdzon R, Paczek L. Zielniok K, et al. Cells. 2020 Nov 1;9(11):2396. doi: 10.3390/cells9112396. Cells. 2020. PMID: 33139632 Free PMC article.
Vadadustat caused a marked decrease in the secretion of IL6 (by 51%), HGF (by 47%), CCL7 (MCP3) (by 42%) and CXCL8 (by 40%). ...Preconditioning with Vadadustat may constitute a valuable approach to improve the therapeutic properties of MSCs....
Vadadustat caused a marked decrease in the secretion of IL6 (by 51%), HGF (by 47%), CCL7 (MCP3) (by 42%) and CXCL8 (by 40%). ...Preco …
The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
Imai E, Imai A. Imai E, et al. Intern Med. 2023 Nov 6. doi: 10.2169/internalmedicine.2501-23. Online ahead of print. Intern Med. 2023. PMID: 37926547 Free article.
Methods The primary outcome of this study was the change in dose and cost from the initiation of vadadustat and daprodustat treatment. The secondary outcome was the drug safety. ...After six months, the Hb level reached 12.1 g/dL and 11.3 g/dL for daprodustat and vadadu …
Methods The primary outcome of this study was the change in dose and cost from the initiation of vadadustat and daprodustat treatment …
Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO(2)TECT Randomized Clinical Trial of ESA-Naive Patients.
Winkelmayer WC, Arnold S, Burke SK, Chertow GM, Eckardt KU, Jardine AG, Lewis EF, Luo W, Matsushita K, McCullough PA, Minga T, Parfrey PS. Winkelmayer WC, et al. Kidney Med. 2023 May 12;5(7):100666. doi: 10.1016/j.xkme.2023.100666. eCollection 2023 Jul. Kidney Med. 2023. PMID: 37427293 Free PMC article.
RATIONALE & OBJECTIVE: Prespecified analyses of the PRO(2)TECT trials comparing the safety of the oral hypoxia-inducible factor prolyl hydroxylase inhibitor vadadustat with darbepoetin alfa in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) found …
RATIONALE & OBJECTIVE: Prespecified analyses of the PRO(2)TECT trials comparing the safety of the oral hypoxia-inducible factor prolyl h …
79 results